The European Medicines Agency (EMA) is due to provide an assessment on Thursday of the safety of Astrazeneca's vaccine against Covid-19 after several countries temporarily suspended use of the jab over fears about side effects.
The EMA's safety committee has been making a detailed evaluation of a small number of cases concerning blood clots occurring in recipients of the vaccine, reports dpa news agency.
The Agency's Pharmacovigilance Risk Assessment Committee (PRAC) is to issue any necessary recommendations for further action after its meeting on Thursday.
The European nations that has halted the usage of the vaccine are France Germany, Italy, Spain, Slovenia, Cyprus, Portugal,Austria, Bulgaria, Denmark, Romania, Estonia, Lithuania, Luxembourg, Latvia, the Netherlands, as well as non-EU countries of Norway and Iceland.
Many said they were waiting for guidance from the EMA.
The EMA said it was looking at available data related to all thromboembolic events reported after vaccination, including additional data provided by national health agencies.
"Rapid and thorough analysis of the available data and clinical circumstances surrounding specific cases is continuing, to determine whether the vaccine might have contributed or if events are likely to have been due to other causes," the EMA said.
Both the EMA and the World Health Organization (WHO) recommended continuing inoculation with AstraZeneca's vaccine until further notice, noting its benefits outweighed the risks of Covid-19.
--IANS
ksk/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)